MANF Therapeutics Receives Notices of Allowance Co
Post# of 30067
(Total Views: 840)
Posted On: 01/17/2019 7:09:26 AM
MANF Therapeutics Receives Notices of Allowance Covering MANF Use as Treatment for Parkinson's in Europe and Diabetes in Japan
Download as PDF
JANUARY 17, 2019
New York, NY, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) in pre-clinical development advancing mesencephalic astrocyte-derived neurotrophic factor (MANF) as a disease-modifying treatment for orphan ophthalmological conditions and neurodegenerative diseases, today announced it has received a notice of allowance from the European Patent Office covering the use of MANF as a treatment for various neurodegenerative disorders, including Parkinson’s disease, as well as a notice of allowance from the Japanese Patent Office covering the use of MANF as a treatment for diabetes and other beta-cell disorders.
MANF has significant therapeutic potential across multiple orphan ophthalmological conditions such as RAO, and retinitis pigmentosa, where MANF has already received orphan drug designations from the FDA, Wolfram’s Syndrome, as well as in larger indications such as Glaucoma, Parkinson’s disease, diabetes and cardiovascular disease, including stroke and myocardial infarction. MANF Therapeutics is the front-runner and primary worldwide intellectual property (IP) holder for MANF-based therapies including protein therapy, gene therapy and cell therapy. The Company owns rights to composition of matter patents and patent applications for MANF and owns, or has licenses to, method of use patents and patent applications covering the use of MANF in ophthalmology, neurology and diabetes, as well as other immune system-related applications.
https://www.amarantus.com/news/press-releases...e-covering
Download as PDF
JANUARY 17, 2019
New York, NY, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) in pre-clinical development advancing mesencephalic astrocyte-derived neurotrophic factor (MANF) as a disease-modifying treatment for orphan ophthalmological conditions and neurodegenerative diseases, today announced it has received a notice of allowance from the European Patent Office covering the use of MANF as a treatment for various neurodegenerative disorders, including Parkinson’s disease, as well as a notice of allowance from the Japanese Patent Office covering the use of MANF as a treatment for diabetes and other beta-cell disorders.
MANF has significant therapeutic potential across multiple orphan ophthalmological conditions such as RAO, and retinitis pigmentosa, where MANF has already received orphan drug designations from the FDA, Wolfram’s Syndrome, as well as in larger indications such as Glaucoma, Parkinson’s disease, diabetes and cardiovascular disease, including stroke and myocardial infarction. MANF Therapeutics is the front-runner and primary worldwide intellectual property (IP) holder for MANF-based therapies including protein therapy, gene therapy and cell therapy. The Company owns rights to composition of matter patents and patent applications for MANF and owns, or has licenses to, method of use patents and patent applications covering the use of MANF in ophthalmology, neurology and diabetes, as well as other immune system-related applications.
https://www.amarantus.com/news/press-releases...e-covering
(5)
(0)